Advances in genomic and pharmacokinetic profiling for clinical stratification of metastatic breast cancer.

ABSTRACT:

Background

Metastatic breast cancer (MBC) is the most significant clinical challenge in patient care; hence, we need new personalized therapeutic targets and innovative inhibitors. Genomic, proteomic, and structural analysis can be a pivotal tool for faster and more cost-efficient lead discovery.

Methods

The study employed gene expression profiling (Microarray, PCR, Bulk RNA-Seq) and computer-aided drug design, including structural modeling, virtual screening, docking, pharmacophore modeling, ADMET analysis, and NMA dynamics. A large compound library was screened to identify stable, high-affinity protein-ligand interactions targeting key proteins in metastatic breast cancer.

Results

Across primary breast tumors and metastatic organs (lung, liver, bone, and brain), we

SUBMITTER: Attique Z 

PROVIDER: S-EPMC12799884 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature